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Introduction
Several recent trials have demonstrated superiority with
the addition of rituximab to traditional chemotherapeutic
regimens in HIV-negative non-Hodgkin lymphoma (NHL)
patients. In HIV-positive patients, the benefit of adding
rituximab is less clear. In a randomized controlled trial,
the addition of rituximab to CHOP showed no survival
advantage. We performed a study-level meta-analysis of
prospective studies to ascertain outcomes in HIV+ NHL
patients treated with CHOP vs. R-CHOP.
Methods
We performed a Pubmed/MEDLINE literature search from
January 1990 through June 2011, with search terms “(HIV
OR AIDS) AND lymphoma AND rituximab” and limited
our results to English language prospective trials with
either CHOP or R-CHOP in HIV+ NHL. Characteristics
and outcomes were collected from published data. Chi-
square was used to compare the characteristics between
groups. The main outcomes were overall response rate
(ORR), complete response (CR) rate and 2-year overall
survival (OS) and will be reported as odds ratio (OR).
Results
We identified 3 studies on HIV+ NHL patients treated
with R-CHOP and 9 with CHOP from a total of 119 publi-
cations. Nine studies (75%) administered Pneumocytis
jirovecci pneumonia prophylaxis. Four studies (33%) admi-
nistered prophylactic intrathecal chemotherapy, and in 3
(25%) it was optional. Four studies (33%) administered
G-CSF routinely, and 3 studies (25%) only if grade 3/4 neu-
tropenia occurred. A total of 810 patients were studied, 569
treated with CHOP and 241 with R-CHOP. The median
age was 38 and 43 years for CHOP and R-CHOP, respec-
tively, with 86% and 85% of male patients, respectively
(p=0.98). With regard to HAART, 68% of patients treated
with CHOP and 92% with R-CHOP were on HAART prior
to lymphoma diagnosis (p<0.0001). The median CD4
count was 109 and 136 cells/mm
3 in CHOP and R-CHOP
patients, respectively. Clinically, 65% and 54% of CHOP
patients presented with advanced stage and age-adjusted
International Prognostic Index (aaIPI) score 2-3, while the
proportion was 74% and 45% in R-CHOP, respectively
(p=0.02 for stage and p=0.03 for aaIPI scores). The OR for
ORR, CR and 2-year OS in patients treated with R-CHOP
vs. CHOP was 1.05 (95% CI 0.71-1.55; p=0.81), 1.42 (95%
CI 1.04-1.93; p=0.03) and 2.37 (95% CI 1.73-3.25;
p<0.0001), respectively.
Conclusions
HIV+ NHL patients treated with R-CHOP had higher
odds for CR and 2-year OS (42% and 137%, respectively)
when compared to CHOP. However, patients treated
with R-CHOP also had higher rates of HAART adminis-
tration, higher CD4 counts and lower aaIPI scores.
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